OPEN EDUCATIONAL RESOURCES

UPA PERPUSTAKAAN UNEJ | NPP. 3509212D1000001

  • Home
  • Admin
  • Select Language :
    Arabic Bengali Brazilian Portuguese English Espanol German Indonesian Japanese Malay Persian Russian Thai Turkish Urdu

Search by :

ALL Author Subject ISBN/ISSN Advanced Search

Last search:

{{tmpObj[k].text}}
Image of From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Bookmark Share

Text

From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline

Tulum, Öner - Personal Name; Andreoni, Antonio - Personal Name; Lazonick, William - Personal Name;

The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth.


Availability

No copy data

Detail Information
Series Title
-
Call Number
615.1 TUL f
Publisher
: Cambridge University Press., 2022
Collation
-
Language
English
ISBN/ISSN
9781009278140
Classification
615.1
Content Type
text
Media Type
computer
Carrier Type
online resource
Edition
-
Subject(s)
Obat-Obatan, Farmasi, Farmakologi
Specific Detail Info
-
Statement of Responsibility
Öner Tulum, Antonio Andreoni and William Lazonick
Other Information
Cataloger
Erwin Hendarto
Source
https://doi.org/10.1017/9781009278140
Validator
-
Other version/related

No other version available

File Attachment
  • From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Comments

You must be logged in to post a comment

OPEN EDUCATIONAL RESOURCES

Search

start it by typing one or more keywords for title, author or subject


Select the topic you are interested in
  • Computer Science, Information & General Works
  • Philosophy & Psychology
  • Religion
  • Social Sciences
  • Language
  • Pure Science
  • Applied Sciences
  • Art & Recreation
  • Literature
  • History & Geography
Icons made by Freepik from www.flaticon.com
Advanced Search
Where do you want to share?